FAKTOR-OPTIONSSCHEIN - ARCS BIOS Stock

Certificat

DE000MG4AJZ7

Market Closed - Börse Stuttgart 02:34:26 2024-07-12 pm EDT
3.44 EUR -0.29% Intraday chart for FAKTOR-OPTIONSSCHEIN - ARCS BIOS
Current month-10.18%
1 month-42.09%
Date Price Change
24-07-12 3.44 -0.29%
24-07-11 3.45 +54.71%
24-07-10 2.23 -10.08%
24-07-09 2.48 +4.20%
24-07-08 2.38 -9.51%

Delayed Quote Börse Stuttgart

Last update July 12, 2024 at 02:34 pm EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying ARCUS BIOSCIENCES, INC.
Issuer Morgan Stanley
WKN MG4AJZ
ISINDE000MG4AJZ7
Date issued 2024-05-15
Strike 11.94 $
Maturity Unlimited
Parity 0.83 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 11.84
Lowest since issue 2.22
Spread 0.09
Spread %2.50%

Company Profile

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Sector
-
More about the company

Ratings for Arcus Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Consensus: Arcus Biosciences, Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
15.11 USD
Average target price
33.89 USD
Spread / Average Target
+124.28%
Consensus